Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway - PubMed
3 days ago
- #immunotherapy
- #chemoresistance
- #gallbladder-cancer
- Globo H ceramide (GHCer) is linked to chemoresistance and poor prognosis in advanced gallbladder cancer (GBC).
- GHCer promotes gemcitabine resistance (GR) via the A2AR/cAMP/PKA pathway, leading to ABCG2 upregulation.
- High Globo H expression correlates with shorter survival in GBC patients treated with gemcitabine.
- Anti-Globo H antibody (mAb VK9) or vaccine (OBI-833/OBI-821) reverses GR and enhances gemcitabine efficacy in models.
- OBI-833/821 induces immune responses, reducing Foxp3+ Tregs and increasing CD161+ NK cells in a TAA model.
- Targeting Globo H may improve chemotherapy response in GBC.